Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating

Core Viewpoint - Krystal Biotech, Inc. is recognized as one of the best stocks to buy, with a price target raised to $371 by Jefferies analyst Roger Song, reflecting strong revenue growth and promising pipeline developments [1][3]. Financial Performance - For Q4, Krystal Biotech reported revenue of $107.1 million, surpassing the consensus estimate of $105.13 million [3]. - The company experienced re-accelerated revenue growth for Vyjuvek and DEB in the U.S., with penetration reaching approximately 60% [1]. Pipeline and Growth Potential - The company's pipeline is advancing, with two ophthalmology programs in pivotal trials and data expected in 2026, alongside two additional programs nearing pivotal stages [1]. - The FDA granted Regenerative Medicine Advanced Therapy designation to KB707 for treating advanced or metastatic non-small cell lung cancer, supported by early clinical evidence showing consistent antitumor activity [4]. Company Overview - Krystal Biotech is a commercial-stage biotechnology company focused on developing genetic medicines for diseases with high unmet medical needs in the U.S. [5].